این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
International Journal of Hematology-Oncology and Stem Cell Research، جلد ۱۱، شماره ۲، صفحات ۱۱۴-۱۲۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Aberrant Methylation-Mediated Suppression of APAF1 in Myelodysplastic Syndrome
چکیده انگلیسی مقاله Background: Myelodysplastic syndromes (MDSs) include a diverse group of clonal bone marrow disorders characterized by ineffective hematopoiesis and pancytopenia.It was found that down regulation of APAF1, a putative tumor suppressor gene (TSG),leads to resistance to chemotherapy and disease development in some cancers. In this study, we investigated the relation of APAF1 methylation status with its expression and clinicopathological factors in myelodysplastic syndrome (MDS) patients. Materials and Methods: Methylation Sensitive-High Resolution Melting Curve Analysis (MS-HRM) was employed in studying the methylation of CpG islands in the APAF1promoter region in MDS. Gene expression was analyzed by using real time RT-PCR. Results: 42.6% of patient samples were methylated in promoter region of APAF1 analyzed, while methylation of the genewas not seen in controls (P< 0.05). Methylation of APAF1 was significantly associated with the suppression of its mRNA expression (P=0.00). The methylation status of APAF1in advanced-stage MDS patients (80%) was significantly higher than that of the early-stage MDS patients (28.2%) (P=0.001). The difference in frequency of hypermethylated APAF1 gene was significant between good (37.5%) and poor (85.71%) cytogenetic risk groups (P=0.043). In addition, a higher frequency of APAF1 hypermethylation was observed in higher-risk MDS group (69.2%) compared to lower-risk MDS group (34.14%) (P=0.026). Conclusion: Our study indicated that APAF1hypermethylation in MDS was associated to high-risk disease classified according to the IPSS, WHO and cytogenetic risk.
کلیدواژه‌های انگلیسی مقاله HRM,Methylation,Myelodysplastic syndrome,APAF1
نویسندگان مقاله فرهاد ذاکر | farhad zaker
cellular and molecular research center, iran university of medical sciences dept. of haematology, school of allied medicine, iran university of medical sciences

سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (Iran university of medical sciences)

ناهید نصیری | nahid nasiri
dept. of haematology, school of allied medicine, iran university of medical sciences

سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (Iran university of medical sciences)

ناصر امیری زاده | naser amirizadeh
blood transfusion research center, high institute for education and research in transfusion medicine

سازمان اصلی تایید شده: سازمان انتقال خون ایران (Blood transfusion research center)

سید محسن رضوی | seyed mohsen razavi
hematology and oncology department, firoozgar hospital, iran university of medical sciences

سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (Iran university of medical sciences)

مرجان یغمایی | marjan yaghmaie
hematology, oncology and stem cell transplantation research center, tehran university of medical science

سازمان اصلی تایید شده: دانشگاه تهران (Tehran university)

لادن تیموری طولابی | ladan teimoori toolabi
molecular medicine department, biotechnology research center, pasteur institute of iran

سازمان اصلی تایید شده: انستیتو پاستور ایران (Pasteur institute of iran)

علی ملکی | ali maleki
dept of haematology, school of allied medicine, tehran university of medical sciences

سازمان اصلی تایید شده: دانشگاه علوم پزشکی تهران (Tehran university of medical sciences)

معصومه بخشایش | masoumeh bakhshayesh
cellular and molecular research center, iran university of medical sciences

سازمان اصلی تایید شده: دانشگاه علوم پزشکی ایران (Iran university of medical sciences)

نشانی اینترنتی http://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/590
فایل مقاله اشکال در دسترسی به فایل - ./files/site1/rds_journals/78/article-78-350000.pdf
کد مقاله (doi)
زبان مقاله منتشر شده en
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده Articles
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات